Table 1_Impact of vasopressin-assisted laparoscopic endometrioma excision on ovarian reserve: a randomized controlled trial.docx

Outcomes were analyzed using intention-to-treat and per-protocol approaches. Longitudinal changes in AMH were evaluated using linear mixed-effects models.</p>Results<p>In the intention-to-treat analysis, vasopressin injection significantly reduced the time required for cyst stripping (8.9 ± 7.9 vs. 14.4 ± 13.7 min, p = 0.054) and bleeding control (2.2 ± 2.5 vs. 6.5 ± 6.8 min, p = 0.002) compared with the control group.

However, the decline in AMH levels at 12 months after surgery did not differ significantly between the vasopressin and control groups (−0.96 ± 1.11 vs. −1.14 ± 0.92 ng/mL, p = 0.488). Subgroup analyses according to baseline AMH levels (<3 ng/mL and 3.0–<7.0 ng/mL) yielded similar findings. Linear mixed-effects modeling demonstrated a significant decline in AMH at 3 months after surgery, followed by partial recovery at 6 and 12 months, with no significant group-by-time interaction (p = 0.816).

Per-protocol analyses produced consistent results. Histopathological evaluation revealed no significant between-group differences in the thickness or proportion of excised ovarian tissue.</p>Conclusion<p>Although vasopressin reduced operative time and electrocoagulation exposure during endometrioma surgery, it did not prevent postoperative decline in ovarian reserve.</p>